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BACKGROUND: We analysed the outcomes of 726 cases of primary head and neck cancer patients managed between 1996 and 2008,
including those managed in the multidisciplinary clinic or team setting (MDT) and those managed outside of an MDT by individual
disciplines (non-MDT) in the same institution.
METHODS: Data were collected from the Hospital Based Cancer Registry and a database within the Head and Neck Cancer Clinic.
Univariable comparisons and multivariable analyses were performed using a logistic regression model. Survival by staging was
analysed. Comparisons of management and outcomes were made between MDT and non-MDT patients.
RESULTS: 395 patients (54%) had been managed in the MDT vs 331 patients (46%) non-MDT. MDT patients were more likely to have
advanced disease (likelihood ratio w
2¼44.7, Po0.001). Stage IV MDT patients had significantly improved 5-year survival compared
with non-MDT patients (hazard ratio¼0.69, 95% CI¼0.51–0.88, P¼0.004) and more synchronous chemotherapy and
radiotherapy (P¼0.004), and the non-MDT group had more radiotherapy as a single modality (P¼0.002).
CONCLUSIONS: The improved survival of MDT-managed stage IV patients probably represents both the selection of multimodality
treatment and chemotherapeutic advances that these patients received in a multidisciplinary team setting by head and neck cancer
specialists as opposed to cancer generalists in a non-MDT setting.
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Head and neck (H&N) cancers are a complex, heterogeneous
group of malignancies, which require multifaceted treatment
strategies and the input of a number of specialities. To facilitate
timely and appropriate evidence-based management of H&N
cancer cases, most centres have now established multidisciplinary
team meetings (MDT) in which each of the medical and allied
health specialities are represented so that accurate tumour staging
and treatment plans can be best tailored to individuals (Expert
Advisory Group on Cancer, 1995; Taylor et al, 2010).
A challenge for service providers is the lack of level I evidence in
H&N cancer management. An MDT provides a combination of
evidence-based management, local experience and availability of
treatment modalities. The assumed benefits of the MDT include
improvements in communication between health professionals,
coordination and continuity of care and better clinical outcomes
(Westin and Stalfors, 2008). Despite this, MDTs are costly, and
their benefits in improving outcomes in the management of H&N
cancer have not been widely studied (Westin and Stalfors, 2008;
Taylor et al, 2010).
The Sir Charles Gairdner Hospital Based Cancer Registry
(HBCR) was started in 1996 for systematic collection of data on
patients with certain primary cancers, including H&N malignan-
cies. A weekly H&N Cancer MDT is attended by otolaryngologists,
plastic surgeons, radiation and medical oncologists, dentists,
dieticians, speech pathologists, radiologists and a nurse cancer
care coordinator. The MDT reviews each new patient’s diagnosis,
imaging, medical and social factors, confirms staging and
formulates a management plan. After initial treatment, cases are
reviewed again at the MDT whenever further treatment is planned.
The MDT follows the National Comprehensive Cancer Network
Clinical Practice Guidelines in Oncology.
Despite the availability of the MDT at SCGH, we recognised that
a large proportion of newly diagnosed patients are still managed by
individual disciplines outside of the MDT, which included
clinicians who were in fact generalists with an interest in H&N
cancer but also clinicians who were members of the MDT.
The primary aim of our study was to analyse the differences in
outcome and survival data between these two groups of H&N
cancer patients managed at SCGH.
MATERIALS AND METHODS
A retrospective 12-year analysis was undertaken, involving data
from the SCGH HBCR and SCGH MDT. This study was approved
by the Sir Charles Gairdner Human Research Ethics Committee
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s(QI no 2444). Patients attending the MDT were entered into a
Microsoft Access database and were also included in the HBCR.
Newly diagnosed primary H&N cancer patients presenting to the
hospital for treatment (MDT and non-MDT) from 1 January 1996
until 1 February 2009, whose complete hospital and HBCR records
were obtainable, were included.
Patient demographics, cancer site, staging, treatment and
outcomes of different modalities and combinations of therapies
were compared. All cases were followed-up for death by the
Registrar General of Western Australia. Statistical methods for
analysis included Cox proportional hazards regression and like-
lihood ratio w
2-tests (LRw
2). Analysis of survival was used to
estimate the hazard ratio (HR), with associated 95% confidence
intervals and P-values. For all analyses, a P-value o0.05 was
interpreted as statistically significant, but for univariable Cox
regression results, the sequential rejection method of Holm was
used to correct the critical significance level for multiple
comparisons (Holm, 1979). Data analysis was conducted using
the Stata package (StataCorp, 2009. Stata Statistical Software
Release 11; StataCorp LP, College Station, TX, USA).
RESULTS
A total of 726 newly diagnosed patients fulfilled the inclusion
criteria (see Figure 1). MDT patients were younger by about
2 years of age on average (P¼0.046), which is a potential source of
bias, as increasing age at diagnosis is associated with a significant
increase in risk of death (HR¼1.04, Po0.001). Survival times were
further analysed for stage I–IV groups individually, and there was
no significant difference in outcomes for stages I–III between
MDT- and non-MDT-treated patients (see Table 1). The numbers
in each of these stages were too small to provide adequate
statistical power. There was, however, a statistically significant
difference in survival for stage-IV patients who were managed by
the MDT (HR¼0.69, 95% CI¼0.51–0.88, P¼0.004; see Figure 2).
Furthermore, patients seen in the multidisciplinary clinic were
more likely to have advanced disease (LRw
2¼44.7, Po0.001),
which would produce bias, suggesting greater risk for that subset
of patients, if stage was not controlled for in the analysis.
Analysis of therapy variables suggests that the multidisciplinary
clinic has a substantial influence on treatment decisions. Patients
seen in the multidisciplinary clinic were significantly less likely to
receive radiotherapy alone for positive nodes (LRw
2¼16.08,
Po0.001), significantly less likely to receive surgical treatment
alone for their cancer (LRw
2¼10.74, Po0.001) and positive nodes
(LRw
2¼19.42, Po0.0001). There was an increasing incidence in
the use of combination chemotherapy and radiotherapy from
12.5% in 1996 to 45% in 2008 (Cuzick test for trend, Po0.001;
Cuzick, 1985) and a concomitant decline in the use of radiotherapy
alone from 27.1% in 1996 to 15% in 2008 (Cuzick test for trend,
Po0.001). Synchronous chemotherapy and radiotherapy increased
from 2.1% in 1996 to 42.5% in 2008 (Cuzick test for trend,
Po0.001). Combination surgery, chemotherapy and radiotherapy
increased from 6.3% in 1996 to 12.5% in 2008. There was a clear
difference in treatment modalities in the MDT vs non-MDT group.
The MDT has more synchronous chemotherapy and radiotherapy
(P¼0.004) and the non-MDT group has significantly more
radiotherapy as a single modality (P¼0.002).
DISCUSSION
Despite widespread implementation of MDTs in cancer manage-
ment in a number of countries, robust evidence to suggest
improvement in outcomes in patients with H&N cancer is lacking,
which contributes to scepticism regarding MDT patient manage-
ment. The literature suggests that MDT time delays and expense
are some potential reasons why treating doctors believe that
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Figure 1 Head and neck cancer patients seen at MDT and non-MDT,
1996–2008.
Table 1 H&N cancers, 1996–2008
Seen at MDT
Difference
between
MDT and
non-MDT
Difference
in survival
No (%) Yes (%) PP
Tumour site
Oral cavity 49 (14.8) 92 (23.3) 0.003 0.761
Oropharynx 74 (22.3) 116 (29.4) 0.03 0.665
Nasopharynx 17 (5.12) 11 (2.78) 0.103 0.044
Hypopharynx 16 (4.82) 13 (3.29) 0.295 o0.001
Larynx 93 (28.0) 90 (22.8) 0.106 0.048
Nasal cavity/sinus 42 (12.7) 39 (9.87) 0.237 0.01
Salivary glands 36 (10.8) 25 (6.33) 0.029 0.012
Other 5 (1.51) 9 (2.28) 0.446 0.174
Total 332 (100) 395 (100)
Treatment modality o0.001
Chemotherapy only 2 (0.87) 2 (0.76) 0.862 0.009
Surgery only 31 (13.4) 42 (16.0) 0.562 0.08
Radiotherapy only 120 (52.0) 83 (31.7) o0.001 0.028
Radiotherapy+
chemotherapy
27 (11.7) 28 (10.7) 0.002 0.572
Radiotherapy+
chemotherapy+surgery
16 (6.9) 18 (6.9) 0.868 0.189
Synchronous
chemotherapy
35 (15.2) 89 (34.0) o0.001 0.039
Total 231 (100) 262 (100)
Abbreviations: H&N¼head and neck; MDT¼multidisciplinary team. Grouping
according to the UICC (Union for International Cancer Control) TNM version 6 and
treatment pattern overall.
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Figure 2 Kaplan–Meier survival curves for H&N cancer patients for all
stages and Kaplan–Meier survival curves for H&N cancer patients: stage-IV
cases only.
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searly-stage H&N cancers can be successfully managed outside of
an MDT, principally referring patients with advanced malignancy
(Taylor and Ramirez, 2009). Apart from influencing treatment
decisions, MDTs have also been shown to improve cancer staging
and subsequently patient outcomes (Stephens et al, 2006).
Consequences of non-MDT management include the possibility
of less accurate staging, lack of allied health input and loss to
follow-up, due to the lack of coordinated care, as is available in
MDT settings. A search of the medical literature reveals a number
of cohort studies from single centres or regions that have
demonstrated survival benefits linking MDT management in a
range of malignancies. (Junor et al, 1994; Birchall et al, 2004;
Morris et al, 2006; Stephens et al, 2006). However, they are subject
to bias and therefore it is difficult to say whether results from one
centre can be extrapolated to another centre (Expert Advisory
Group on Cancer, 1995). Nevertheless, in the absence of level I or II
data, these studies form the basis of clinical guideline formulation
and inform current best practice.
A surprisingly high proportion of H&N cancer patients at SCGH
were managed independently of the MDT by various disciplines,
including otolaryngology, plastic surgery, general surgery, radia-
tion oncology and medical oncology. This presented a unique
opportunity to analyse the potential differences in management
and outcomes between the two cohorts of patients. Investigating
the reasons why some of our colleagues never referred or
inconsistently referred all H&N cancer patients to the MDT was
beyond the scope of this study. However, we do acknowledge that
this may be a potential source of bias in reporting our results.
Our results indicate two principal findings. First, there is a
significant increase in survival for patients managed through the
MDT when stage, age at diagnosis and year of diagnosis are
controlled for in the analysis. Second, the use of a selection of
multimodality therapy treatment options is significantly associated
with management of patients by the MDT and it seems likely that
this is also the cause of the reduced risk of death for MDT. These
findings may be explained by the fact that H&N cancer specialists
(MDT) as opposed to cancer generalists (non-MDT) are involved
in management and that a large proportion of the non-MDT
patients were treated more than 10 years ago when advances in
chemotherapeutic therapies were not yet present. The adoption of
these recent chemotherapeutic advances in the MDT may account
for increased survival of stage-IV MDT-treated patients.
The results of this study have been openly discussed with all our
colleagues in our institution and we have recommended adherence
to evidence-based guidelines and management of all H&N cancer
cases in an MDT irrespective of staging. In the last 12 months since
the release and discussion of these findings, opinions and
viewpoints regarding the H&N cancer MDT have shifted to an
increase in patient referrals of all cancer stages. A repeat audit of
patient outcomes in the future is recommended.
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